DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1669.52T
5Y Perf.-59.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
DBVT vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
ALKS
Alkermes plc
Biotechnology
Market Cap$6.12B
5Y Perf.+121.6%
DBVT vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DBVT | ALKS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1669.52T | $6.12B |
| Revenue (TTM) | $0.00 | $1.48B |
| Net Income (TTM) | $-168M | $242M |
| Gross Margin | — | 86.3% |
| Operating Margin | — | 17.2% |
| Forward P/E | — | 25.3x |
| Total Debt | $22M | $70M |
| Cash & Equiv. | $194M | $1.12B |
DBVT vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DBVT
ALKS
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| DBV Technologies S.… (DBVT) | 100 | 40.2 | -59.8% |
| Alkermes plc (ALKS) | 100 | 221.6 | +121.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DBVT vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALKS leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. DBV Technologies S.A. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.7% vs ALKS's +15.4%
Best for: income & stability
ALKS
Alkermes plc
The Growth Play
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -4.6% 10Y total return vs DBVT's -87.1%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALKS | -5.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | ALKS | 16.4% margin vs DBVT's 0.3% |
| Stability / Safety | ALKS | Beta 1.06 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | DBVT | +110.7% vs ALKS's +15.4% |
| Efficiency (ROA) | ALKS | 10.5% ROA vs DBVT's -89.0% |
DBVT vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
DBVT vs ALKS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALKSLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
ALKSAlkermes plc
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
DBVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ALKS5/6
Risk & VolatilityBeta, volatility, and downside exposure
ALKS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.5B and $0 in trailing revenue.
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.5B |
| EBITDAEarnings before interest/tax | -$112M | $281M |
| Net IncomeAfter-tax profit | -$168M | $242M |
| Free Cash FlowCash after capex | -$151M | $480M |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +17.2% |
| Net MarginNet income ÷ Revenue | — | +16.4% |
| FCF MarginFCF ÷ Revenue | — | +32.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +91.5% | -67.0% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
DBVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| Market CapShares × price | $1669.52T | $6.1B |
| Enterprise ValueMkt cap + debt − cash | $1669.52T | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.74x | 25.35x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 18.02x |
| Price / SalesMarket cap ÷ Revenue | — | 4.14x |
| Price / BookPrice ÷ Book value/share | 0.64x | 3.36x |
| Price / FCFMarket cap ÷ FCF | — | 12.73x |
DBVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ALKS delivers a 14.5% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| ROE (TTM)Return on equity | -130.2% | +14.5% |
| ROA (TTM)Return on assets | -89.0% | +10.5% |
| ROICReturn on invested capital | — | +18.9% |
| ROCEReturn on capital employed | -145.7% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.13x | 0.04x |
| Net DebtTotal debt minus cash | -$172M | -$1.0B |
| Cash & Equiv.Liquid assets | $194M | $1.1B |
| Total DebtShort + long-term debt | $22M | $70M |
| Interest CoverageEBIT ÷ Interest expense | -189.82x | 24.74x |
ALKS leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ALKS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,440 today (with dividends reinvested), compared to $3,041 for DBVT. Over the past 12 months, DBVT leads with a +110.7% total return vs ALKS's +15.4%. The 3-year compound annual growth rate (CAGR) favors ALKS at 7.2% vs DBVT's 5.7% — a key indicator of consistent wealth creation.
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| YTD ReturnYear-to-date | +2.3% | +28.3% |
| 1-Year ReturnPast 12 months | +110.7% | +15.4% |
| 3-Year ReturnCumulative with dividends | +18.1% | +23.1% |
| 5-Year ReturnCumulative with dividends | -69.6% | +64.4% |
| 10-Year ReturnCumulative with dividends | -87.1% | -4.6% |
| CAGR (3Y)Annualised 3-year return | +5.7% | +7.2% |
ALKS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 99.2% from its 52-week high vs DBVT's 74.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.26x | 1.06x |
| 52-Week HighHighest price in past year | $26.18 | $36.55 |
| 52-Week LowLowest price in past year | $7.53 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +74.4% | +99.2% |
| RSI (14)Momentum oscillator 0–100 | 43.7 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 249K | 2.3M |
ALKS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates DBVT as "Buy" and ALKS as "Buy". Consensus price targets imply 137.7% upside for DBVT (target: $46) vs 21.4% for ALKS (target: $44).
| Metric | DBVTDBV Technologies … | ALKSAlkermes plc |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $46.33 | $44.00 |
| # AnalystsCovering analysts | 15 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALKS leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallAlkermes plc (ALKS)Leads 3 of 6 categories
Loading custom metrics...
DBVT vs ALKS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DBVT or ALKS a better buy right now?
Alkermes plc (ALKS) offers the better valuation at 25.
3x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DBVT or ALKS?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +64.
4%, compared to -69. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ALKS returned -4. 6% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DBVT or ALKS?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 19% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — DBVT or ALKS?
On earnings-per-share growth, the picture is similar: Alkermes plc grew EPS -34.
1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DBVT or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DBVT or ALKS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DBVT or ALKS better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
06)). Both have compounded well over 10 years (ALKS: -4. 6%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DBVT and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.